The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
British Association of Dermatologists’ guidelines for the management of lichen sclerosus 2010
Open accessAbstract
One of the aims of the British Association of Dermatologists (BAD) is to provide guidelines for the management of skin diseases using all available good‐quality evidence‐based data. The BAD guidelines writing and consultation process, and its revised formats, have been described elsewhere.1 2–3 These guidelines for the management of lichen sclerosus (LS) have been prepared for dermatologists on behalf of the BAD. They present evidence‐based guidance for investigation and treatment, with identification of the strength of evidence available at the time of preparation of the guidelines. The guidelines have been revised and updated in accordance with a predetermined scope, based on that used in the 2002 guidelines. Recommendations in these guidelines supersede those in the 2002 guidelines. The overall objective of the guidelines is to provide up‐to‐date recommendations for the management of LS in adults and children. This guidance has been written by dermatologists and has been shown to a patient. The guidelines have also been seen by a urologist, gynaecologist and genitourinary physician, all of whom are involved in the management of patients with LS. These guidelines have been developed using the BAD’s recommendations3 and also with reference to the AGREE (Appraisal of Guidelines Research and Evaluation) instrument.4 Medline and EMBASE databases were searched from 2002 to 2009 and full relevant papers obtained. The draft guidelines were made available for consultation and review by the BAD membership; the final document was peer reviewed by the Clinical Standards Unit of the BAD (made up of the Therapy & Guidelines and Audit & Clinical Standards Subcommittees) prior to publication. There are few published randomized controlled trials to support the following guidelines for the management of LS; the recommendations made are those that are currently considered best practice but they will be modified at intervals in the light of new evidence. LS, although a dermatosis, occurs commonly at a genital site and consequently is not only managed by dermatologists; patients may be under the care of other specialist disciplines. There have been many long‐standing difficulties in the appraisal and grading of the evidence for the treatment of LS. Historically, the nomenclature used to describe LS has been unclear. In addition, there may be difficulty in assessing the number of patients with active disease as, although asymptomatic, there is still ongoing activity as evidenced by scarring. There are also instances where the LS may be in remission but the patient still experiences symptoms due to a secondary sensory disorder, or additional irritant eczema. These guidelines will be revised as necessary to reflect changes in practice. These guidelines have been prepared for dermatologists on behalf of the BAD and reflect the best data available at the time the report was prepared. Caution should be exercised in interpreting the data; the results of future studies may require alteration of the conclusions or recommendations in this report. It may be necessary or even desirable to depart from the guidelines in the interests of specific patients and special circumstances. Just as adherence to guidelines may not constitute defence against a claim of negligence, so deviation from them should not necessarily be deemed negligent. LS is an autoimmune, inflammatory dermatosis, characterized by a lymphocytic response that has a predilection for the genital skin in both sexes, and an association with several other autoimmune diseases. The aetiology of LS is uncertain but there is mounting evidence to suggest that autoimmune mechanisms are involved in its pathogenesis;5 6–7 there is an increased incidence of tissue‐specific antibodies8 and associations with other autoimmune diseases in patients with LS,9, 10 as well as positive associations with HLA class II antigens.11 12–13 There is still controversy regarding the implication of Borrelia infection as an aetiological agent; although several studies have shown that this association does not occur in the U.S.A., some doubt still remains in Europe.14, 15 The presence of circulating extracellular matrix protein antibodies gives further support to an immune aetiopathology in female patients.16‘Balanitis xerotica obliterans’ is now viewed as a synonymous term describing LS of the penis, and ‘kraurosis vulvae’ is now recognized as LS of the vulva. The term ‘leucoplakia’ (meaning white plaque) is not a diagnostic entity and is descriptive only, as many conditions may present with white plaques. The term ‘lichen sclerosus et atrophicus’ has been abbreviated to ‘lichen sclerosus’ as some cases are associated with a hypertrophic, rather than atrophic, epithelium. There are instances when it can be difficult to differentiate between LS and lichen planus (LP) on the basis of the clinical and histological features; these cases appear to constitute an overlap syndrome, which is often associated with sq
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vulvar Lichen Sclerosus: Pathophysiology and Treatment
Smith, Y. R., & Haefner, H. K. (2004) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200405020-00005 · Cited by 526
Powell, J., & Wojnarowska, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08228-2 · Cited by 515
Meffert, J. J., Davis, B. M., & Grimwood, R. E. (1995) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(95)90060-8 · Cited by 334
The treatment of balanitis xerotica obliterans
Depasquale, I., Park, A. J., & Bracka, A. (2000) · BJU International · doi:10.1046/j.1464-410x.2000.00772.x · Cited by 325
Lichen Sclerosus: Review of the Literature and Current Recommendations for Management
Pugliese, J. M., Morey, A. F., & Peterson, A. C. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.08.024 · Cited by 314
Lichen sclerosus et atrophicus
(2004) · Dermatology Therapy · doi:10.1007/3-540-29668-9_1604 · Cited by 306
Does Treatment of Vulvar Lichen Sclerosus Influence Its Prognosis?
Cooper, S. M., Gao, X.-H., Powell, J. J., & Wojnarowska, F. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.6.702 · Cited by 281
Childhood vulvar lichen sclerosus: An increasingly common problem
Powell, J., & Wojnarowska, F. (2001) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2001.113474 · Cited by 274
Lichen Sclerosus et Atrophicus
Abdullah-Al-Amin, M., Begum, S. N., & Pramanik, M. (1970) · TAJ: Journal of Teachers Association · doi:10.3329/taj.v17i1.3490 · Cited by 261
Cooper, S. M., Ali, I., Baldo, M., & Wojnarowska, F. (2008) · Archives of Dermatology · doi:10.1001/archderm.144.11.1432 · Cited by 239
HARRINGTON, C. I., & DUNSMORE, I. R. (1981) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1981.tb08172.x · Cited by 206
Kulkarni, S., Barbagli, G., Kirpekar, D., Mirri, F., & Lazzeri, M. (2009) · European Urology · doi:10.1016/j.eururo.2008.07.046 · Cited by 203
The association between lichen sclerosus and antigens of the HLA system
MARREN, P., JELL, J., CHARNOCK, F. M., BUNCE, M., WELSH, K., & WOJNAROWSKA, F. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1995.tb05013.x · Cited by 194
Renaud-Vilmer, C., Cavelier-Balloy, B., Porcher, R., & Dubertret, L. (2004) · Archives of Dermatology · doi:10.1001/archderm.140.6.709 · Cited by 191
Lichen sclerosus premenarche: autoimmunity and immunogenetics
Powell, J., Wojnarowska, F., Winsey, S., Marren, P., & Welsh, K. (2000) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2000.03360.x · Cited by 189
DALZIEL, K. L., MILLARD, P. R., & WOJNAROWSKA, F. (1991) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1991.tb00626.x · Cited by 179
Penile Carcinoma in Patients With Genital Lichen Sclerosus: A Multicenter Survey
Barbagli, G., Palminteri, E., Mirri, F., Guazzoni, G. F., Turini, D., & Lazzeri, M. (2006) · The Journal of Urology · doi:10.1016/s0022-5347(05)00735-4 · Cited by 155
Becker, J. C., Houben, R., Vetter, C. S., & Bröcker, E. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-7 · Cited by 141
Hengge, U. R., Krause, W. K. H., Hofmann, H., Stadler, R., Gross, G., Meurer, M., Brinkmeier, T., Frosch, P. J., Moll, I., Fritsch, P. O., et al. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07446.x · Cited by 141
Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review
Kroft, E. B. M., Berkhof, N. J. G., van de Kerkhof, P. C. M., Gerritsen, R. M. J. P., & de Jong, E. M. G. J. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.07.042 · Cited by 137
Lichen Sclerosus et Atrophicus: A Common and Distinctive Cause of Phimosis in Boys
Chalmers, R. J. G., Burton, P. A., Bennett, R. F., Goring, C. C., & Smith, P. J. (1984) · Archives of Dermatology · doi:10.1001/archderm.120.8.1025 · Cited by 133
High Incidence of Balanitis Xerotica Obliterans in Boys with Phimosis: Prospective 10‐Year Study
Kiss, A., Király, L., Kutasy, B., & Merksz, M. (2005) · Pediatric Dermatology · doi:10.1111/j.1525-1470.2005.22404.x · Cited by 132
Lichen sclerosus in adult men: a study of HLA associations and susceptibility to autoimmune disease
Azurdia, Luzzi, V., BYREN, Welsh, Wojnarowska, Marren, & Edwards (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02611.x · Cited by 129
Bousema, M. T., Romppanen, U., Geiger, J. M., Baudin, M., Vähä‐Eskeli, K., Vartiainen, J., & Vuopala, S. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(94)70021-4 · Cited by 124
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
Ormerod, A. D. (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06899.x · Cited by 122
Efficacy of UVA1 phototherapy in 230 patients with various skin diseases
Rombold, S., Lobisch, K., Katzer, K., Grazziotin, T. C., Ring, J., & Eberlein, B. (2008) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2008.00328.x · Cited by 104
The association of lichen sclerosus et atrophicus and autoimmune-related disease in males
THOMAS, R. H. M., Ridley, C. M., & Black, M. M. (1983) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1983.tb00546.x · Cited by 104
Breuckmann, F., Gambichler, T., Altmeyer, P. J., & Kreuter, A. (2004) · BMC Dermatology · doi:10.1186/1471-5945-4-11 · Cited by 97
Childhood vulvar lichen sclerosus. The course after puberty.
Powell, J., & Wojnarowska, F. (2002) · PubMed · Cited by 97
Treatment of Childhood Vulvar Lichen Sclerosus with Potent Topical Corticosteroid
Fischer, G. O., & Rogers, M. (1997) · Pediatric Dermatology · doi:10.1111/j.1525-1470.1997.tb00247.x · Cited by 97
Effect of lichen sclerosus on sexual function and parturition.
Dalziel, K. (1995) · PubMed · Cited by 96
Frequency of application of topical corticosteroids: an overview
Lagos, & Maibach (1998) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1998.02498.x · Cited by 93
Prowse, D. M., Ktori, E., Chandrasekaran, D., Prapa, A., & Baithun, S. I. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08305.x · Cited by 85
Lichen sclerosus et atrophicus and sexual abuse.
Warrington, S. A., & de San Lazaro, C. (1996) · Archives of Disease in Childhood · doi:10.1136/adc.75.6.512 · Cited by 80
Guidelines for the follow-up of women with vulvar lichen sclerosus in specialist clinics
Jones, R. W., Scurry, J., Neill, S., & MacLean, A. (2007) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.05.031 · Cited by 79
Self-citationUltrapotent Topical Corticosteroid Treatment of Childhood Genital Lichen Sclerosus
Garzón, M. C., & Paller, A. S. (1999) · Archives of Dermatology · doi:10.1001/archderm.135.5.525 · Cited by 78
Lichen sclerosus et atrophicus in children misdiagnosed as sexual abuse.
Handfield-Jones, S. E., Hinde, F. R., & Kennedy, C. T. (1987) · BMJ · doi:10.1136/bmj.294.6584.1404 · Cited by 73
UVA1 phototherapy for genital lichen sclerosus
Beattie, P. E., Dawe, R. S., Ferguson, J., & Ibbotson, S. H. (2006) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2006.02082.x · Cited by 73
High prevalence of thyroid disease in patients with lichen sclerosus.
Birenbaum, D. L., & Young, R. C. (2007) · PubMed · Cited by 62
Incidence of preputial lichen sclerosus in adults: Histologic study of circumcision specimens
Aynaud, O., Piron, D., & Casanova, J.-M. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70247-1 · Cited by 61
Kreuter, A., Tigges, C., Gaifullina, R., Kirschke, J., Altmeyer, P. J., & Gambichler, T. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.235 · Cited by 60
Focused Ultrasound Therapy of Vulvar Dystrophies: A Feasibility Study
Li, C., Bian, D.-H., Chen, W., Zhao, C., Yin, N., & Wang, Z. (2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000139835.34168.b0 · Cited by 58
Lichen sclerosus: evidence that immunological changes occur at all levels of the skin
Farrell, Marren, Dean, & Wojnarowska (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.02909.x · Cited by 56
Pimecrolimus Cream 1% in the Treatment of Lichen Sclerosus
Nissi, R., Eriksen, H. A., Risteli, J., & Niemimaa, M. (2006) · Gynecologic and Obstetric Investigation · doi:10.1159/000096736 · Cited by 55
Simonart, T., Lahaye, M., & Simonart, J. M. (2007) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e3180616689 · Cited by 50
Pimecrolimus for the treatment of vulvar lichen sclerosus: a report of 4 cases.
Goldstein, A. T., Marinoff, S. C., & Christopher, K. (2004) · PubMed · Cited by 46
Zawislak, A. A., McCluggage, W. G., Donnelly, R. F., Maxwell, P., Price, J., Dobbs, S. P., McClelland, H. R., Woolfson, A. D., & McCarron, P. A. (2009) · Photodermatology Photoimmunology & Photomedicine · doi:10.1111/j.1600-0781.2009.00410.x · Cited by 44
WALKDEN, Y. C. F. W. V. (1997) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443619768588 · Cited by 39
Open-label trial of cyclosporine for vulvar lichen sclerosus
Başkan, E. B., Turan, H., Tunalı, Ş., Toker, S. Ç., & Sarıcaoğlu, H. (2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.03.006 · Cited by 37
Vulval lichen sclerosus et atrophicus treated with etretinate (Tigason)
Mørk, N., Jensen, P., & Ps, H. (1986) · Acta Dermato Venereologica · doi:10.2340/0001555566363365 · Cited by 33
Diakomanolis, E., Haidopoulos, D., Syndos, M., Rodolakis, A., Stefanidis, K., Chatzipapas, J., & Michalas, S. (2002) · PubMed · Cited by 31
Is carbon dioxide laser treatment of lichen sclerosus effective in the long run?
Windahl, T. (2006) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590600589666 · Cited by 31
The British Association of Dermatologists guidelines for the management of skin disease
Griffiths, C. E. M. (1999) · British Journal of Dermatology · doi:10.1046/j.1365-2133.1999.3029a.x · Cited by 30
Lau, P. W., Cook, N., Andrews, H., Bracka, A., & Sh, M. (1995) · Sexually Transmitted Infections · doi:10.1136/sti.71.4.228 · Cited by 27
Significant Improvement in Extensive Lichen Sclerosus with Tacrolimus Ointment and PUVA
Valdivielso‐Ramos, M., Bueno, C., & Hernánz, J. M. (2008) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200809030-00006 · Cited by 24
Lichen sclerosus and sexual abuse.
Priestley, B. L., & Bleehen, S. S. (1990) · Archives of Disease in Childhood · doi:10.1136/adc.65.3.335-c · Cited by 23
Topical tacrolimus in the management of lichen sclerosus
Edey, K. A., Bisson, D., & Kennedy, C. (2006) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2006.01103.x · Cited by 22
The British Association of Dermatologists therapeutic guidelines: can we AGREE?
Cox, N. H., & Williams, H. C. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05241.x · Cited by 17
Self-citationHydroxycarbamide: a treatment for lichen sclerosus?
Tomson, N., & Sterling, J. C. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07991.x · Cited by 11
Cited by
Diagnosis and Treatment of Lichen Sclerosus: An Update
Fistarol, S. K., & Itin, P. H. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-012-0006-4 · Cited by 415
Long-term Management of Adult Vulvar Lichen Sclerosus: A Prospective Cohort Study of 507 Women
Lee, A., Bradford, J., & Fischer, G. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.0643 · Cited by 400
Evidence‐based (S3) Guideline on (anogenital) Lichen sclerosus
Kirtschig, G., Becker, K., Günthert, A., Jasaitiene, D., Cooper, S., Chi, C. ‐., Kreuter, A., Rall, K. K., Aberer, W., Riechardt, S., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13136 · Cited by 350
Fibrosing connective tissue disorders of the skin: Molecular similarities and distinctions
Canady, J., Karrer, S., Fleck, M., & Bosserhoff, A. K. (2013) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2013.03.005 · Cited by 66
Pediatric Vulvar Lichen Sclerosus—A Review of the Literature
Orszulak, D., Dulska, A., Niziński, K., Skowronek, K., Bodziony, J., Stojko, R., & Drosdzol-Cop, A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18137153 · Cited by 51
Metadata
- Authors
- Neill, S. M., Lewis, F. M., Tatnall, F. M., & Cox, N. H.
- Venue
- British Journal of Dermatology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-09-20
- Volume
- 163
- Issue
- 4
- Pages
- 672-682
- ISSN
- 0007-0963 (ISSN-L)
- OpenAlex
- W2165456905
- Cited by
- 369
- References
- 59
- FWCI
- 22.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.